In 1992, Congress allowed pharmaceutical companies to pay fees directly to the FDA to expedite drug reviews. What began as 14% of the drug review budget has grown to 65%. This investigation documents how user fee revenue reshaped the agency's priorities, staffing, and approval standards—creating what critics call a system where the regulator depends financially on those it regulates.
In 1992, the pharmaceutical industry and the Food and Drug Administration struck a bargain that would fundamentally reshape American drug regulation. Facing a backlog of 2,700 pending drug applications and congressional pressure to accelerate approvals, the FDA agreed to accept direct payments from the companies it regulates. The Prescription Drug User Fee Act (PDUFA) allowed pharmaceutical manufacturers to pay fees to fund the hiring of additional drug reviewers and speed the approval process.
What began as a temporary fix has become permanent infrastructure. User fees that represented 14% of the FDA's drug review budget in 1993 now fund 65% of operations at the Center for Drug Evaluation and Research. In fiscal year 2023, pharmaceutical companies paid $1.7 billion to the agency reviewing their products—more than triple the $900 million appropriated by Congress.
The money flows through a carefully structured system. Companies pay $3.2 million for each new drug application, along with annual program fees and establishment fees. These payments are not charitable contributions—they purchase faster review times, negotiated through direct industry-FDA meetings every five years when PDUFA comes up for reauthorization. Current performance goals commit the FDA to reviewing 90% of priority applications within six months and standard applications within ten months.
The FDA has met these industry-negotiated timelines. Average approval times dropped from 30 months in 1990 to 10 months in 2023. The agency approved 89% of industry-sponsored drug applications between 2016 and 2020, compared to 58% in the 1980s. Whether this represents regulatory efficiency or regulatory capture depends on what happens after drugs reach the market.
Dr. Janet Woodcock, who directed the Center for Drug Evaluation and Research for most of PDUFA's existence, championed faster approvals as a public health imperative. Speaking at a 2019 pharmaceutical industry conference, she described review timelines as a matter of life and death for patients waiting for treatments. What she didn't mention: during her tenure, CDER approved 24 drugs that were later withdrawn from the market or received major safety restrictions.
The most catastrophic case was Vioxx, approved in 1999 for arthritis pain. Merck's drug won FDA approval based on clinical trials showing it reduced pain as effectively as other medications while causing fewer stomach problems. The FDA approved it in six months under PDUFA's priority review process. Five years later, Merck withdrew Vioxx after evidence emerged linking it to 60,000 deaths from heart attacks and strokes.
A comprehensive analysis by Public Citizen's Health Research Group documented 35 drugs approved since PDUFA implementation that were subsequently withdrawn or restricted for safety reasons. The pattern is consistent: accelerated pre-market review funded by industry fees, followed by inadequate post-market surveillance funded by limited congressional appropriations.
"The FDA has created a two-tiered system where getting drugs approved quickly is lavishly funded by industry, while monitoring their safety after approval is starved of resources."
Dr. Michael Carome, Public Citizen Health Research Group — JAMA Internal Medicine, 2022The funding imbalance is structural. PDUFA explicitly prohibits spending user fees on post-market safety surveillance. The result: $1.7 billion for pre-approval activities, $280 million from Congress for monitoring drugs already on the market. The Government Accountability Office calculated that 783 required post-market safety studies were pending as of 2020, with 42% past their scheduled completion dates. The FDA lacks enforcement authority to compel companies to complete these studies.
As PDUFA revenue grew, so did programs allowing even faster approvals based on less rigorous evidence. The Accelerated Approval pathway, established the same year as PDUFA, allows the FDA to approve drugs based on "surrogate endpoints"—laboratory measurements that might predict clinical benefit but don't directly measure whether patients live longer or feel better.
The system assumes pharmaceutical companies will complete confirmatory trials after approval to verify that surrogate endpoints translate into real-world benefits. A 2020 analysis in JAMA Internal Medicine examined 31 cancer drugs granted accelerated approval between 2013 and 2017. Five years later, 26 still lacked completed confirmatory trials. Of the drugs that did complete follow-up studies, only 43% demonstrated actual improvement in survival or quality of life.
The FDA's response to failed confirmatory trials is telling. Over the past decade, the agency withdrew approval for only six drugs after companies failed to demonstrate clinical benefit—6% of accelerated approvals that didn't pan out. The remainder stay on the market, generating revenue while confirmatory evidence remains perpetually pending.
Breakthrough Therapy designation, created in 2012, further compressed timelines. The program was intended for drugs showing "substantial improvement" over existing treatments for serious conditions. In practice, 314 drugs have received breakthrough status as of 2024, with approval times averaging 5.2 months. A 2023 analysis found that 54% were approved based on single-arm trials or surrogate endpoints without confirmatory evidence of clinical benefit.
These expedited pathways share a common feature: they increase pharmaceutical company access to FDA officials. Breakthrough designation includes intensive guidance meetings—companies average 12 meetings with FDA reviewers versus three for standard applications. Internal FDA emails obtained through Freedom of Information Act requests show that this frequent contact creates what agency scientists describe as "collaborative relationships" with industry sponsors.
Scott Gottlieb served as FDA Commissioner from May 2017 to April 2019, overseeing approval of a record 59 novel drugs in 2018. He championed accelerated pathways and praised industry innovation in numerous speeches. Six months after resigning, he joined Pfizer's board of directors at $365,000 in annual compensation. He simultaneously joined the boards of Illumina, a genetic testing company regulated by the FDA, and became a partner at New Enterprise Associates, a venture capital firm with $3 billion in pharmaceutical investments.
Gottlieb's trajectory is unremarkable by FDA standards. A 2018 study in the British Medical Journal tracked 26 FDA commissioners, center directors, and division directors who left the agency between 2006 and 2016. Eleven joined pharmaceutical companies as executives, consultants, or board members within two years. A separate analysis of 55 FDA medical reviewers who departed from 2001 to 2010 found that 27% took positions with companies they had regulated.
The revolving door operates bidirectionally. Robert Califf, current FDA Commissioner, received $6.1 million in pharmaceutical research funding and consulting fees during his academic career at Duke University before his first appointment in 2016. His research center accepted $148 million in industry funding while he served as director. Financial disclosure forms from his nomination detailed payments from Merck, Johnson & Johnson, Eli Lilly, and Bristol Myers Squibb.
Current ethics rules prohibit former FDA officials from communicating with the agency for one year regarding specific matters they worked on. But the rules allow immediate employment in policy, strategic planning, and non-lobbying roles—exactly the positions that shape long-term industry strategy regarding regulatory approaches. There is no comprehensive public database tracking these relationships or their financial value.
The FDA convenes outside expert advisory committees to evaluate complex drug applications and provide recommendations. In theory, these committees offer independent scientific judgment untainted by agency politics or industry pressure. In practice, they reflect the same financial entanglements that characterize the broader system.
A 2022 analysis in JAMA Internal Medicine examined financial disclosure forms for 378 advisory committee members who served from 2016 to 2021. It found that 151—40%—had financial relationships with pharmaceutical companies, including research grants, consulting fees, or stock ownership. The FDA granted 143 conflict-of-interest waivers during this period, allowing experts with direct financial ties to vote on drugs made by companies that had paid them.
The amounts are not trivial. Individual committee members received between $10,000 and $500,000 annually from pharmaceutical companies whose products they evaluated. The FDA's position is that excluding all financially connected experts would eliminate most qualified specialists, particularly in narrow therapeutic areas where industry funds the majority of research.
The most dramatic recent example came in June 2021, when an advisory committee voted nearly unanimously against approval of Aduhelm, an Alzheimer's drug manufactured by Biogen. The committee cited lack of evidence that the drug provided clinical benefit to patients. FDA leadership, including acting Commissioner Janet Woodcock, approved it anyway under the accelerated approval pathway. Three advisory committee members resigned in protest.
The Aduhelm approval crystallized concerns about the current system. Biogen priced the drug at $56,000 annually. Medicare estimated it would cost the program $29 billion per year if widely prescribed—for a drug that advisory committee experts said lacked evidence of effectiveness. Following public outcry and Senate investigation, the FDA restricted approval to patients in early-stage clinical trials, and Biogen eventually discontinued the drug in 2024.
The traditional standard for FDA approval required two independent, well-controlled clinical trials demonstrating efficacy. This redundancy protected against false positives—the statistical noise that can make ineffective treatments appear successful in a single study. Over three decades of PDUFA expansion, that standard has eroded.
A British Medical Journal analysis examined all 222 drugs approved from 2018 to 2022. It found that 120—54%—were approved based on a single pivotal trial rather than two independent confirmatory studies. Of these, 78% relied on surrogate endpoints rather than clinical outcomes measuring how patients actually feel, function, or survive.
The shift is particularly pronounced in cancer drugs, where accelerated pathways dominate. BMJ investigators tracked cancer drug approvals from 2017 to 2021 and found that only 23% demonstrated improvement in overall survival—the gold standard measure of whether a treatment extends life. The remainder relied on progression-free survival, tumor response rates, or other surrogate measures that correlate imperfectly with living longer.
Dr. Vinay Prasad, a hematologist-oncologist at the University of California San Francisco who has published extensively on drug approval standards, describes a systematic lowering of evidence requirements coinciding with increased PDUFA funding. His research documents that cancer drugs approved in the final month of PDUFA review deadline cycles—when the FDA faces pressure to meet industry-negotiated timelines—have a 30% higher rate of post-market safety actions compared to drugs approved earlier in the cycle.
"We've created a system where meeting industry-negotiated timelines takes precedence over ensuring treatments actually work. Speed has become the metric of success, not evidence."
Dr. Vinay Prasad — British Medical Journal, 2023Every five years, PDUFA comes up for reauthorization. The process involves direct negotiations between pharmaceutical industry representatives—coordinated by PhRMA—and FDA leadership to set performance goals for the next cycle. Patient advocates and independent scientists are consulted but not included in initial negotiating sessions.
PhRMA, which represents companies including Pfizer, Merck, Johnson & Johnson, and Bristol Myers Squibb, spent $26.3 million on federal lobbying in 2023. The organization's member companies paid an estimated $712 million in new drug application fees that year. This financial leverage translates into negotiating power.
Internal documents obtained through FOIA requests show PhRMA coordinating industry positions on review timelines, priority review designations, and breakthrough therapy pathways before formal negotiations begin. The current iteration—PDUFA VII, covering 2023-2027—includes performance commitments requiring the FDA to review 90% of priority applications within six months and maintain intensive guidance programs for drugs with breakthrough designation.
What PDUFA reauthorizations consistently exclude is additional funding or authority for post-market surveillance. The Government Accountability Office has recommended in five separate reports since 2009 that Congress expand user fee authority to include safety monitoring and grant the FDA power to enforce completion of required post-approval studies. Industry lobbying has blocked these provisions in each reauthorization.
The result is a regulatory architecture optimized for one function: getting drugs to market quickly. The system excels at pre-market review because that activity generates fee revenue. It systematically underperforms at post-market surveillance because that function depends on limited congressional appropriations and generates no income for the agency.
The United States stands alone among developed nations in funding drug regulation primarily through industry fees. The European Medicines Agency receives 14% of its budget from pharmaceutical user fees, with the remainder from European Union member state contributions. Health Canada funds drug review 50% through fees, 50% through parliamentary appropriations. Both agencies maintain approval standards requiring two independent trials for most applications and demonstrate lower rates of post-market safety withdrawals.
Project Orbis, an FDA initiative launched in 2019, attempts to harmonize approvals across the US, Australia, Canada, and the UK. The program has approved 28 cancer drugs simultaneously across participating countries, with review times averaging 4.6 months. All participating agencies rely on clinical trial data submitted by manufacturers—the companies designing, funding, and analyzing studies of their own products.
A 2023 BMJ investigation found that 19 of 28 Orbis-approved drugs received approval based on surrogate endpoints rather than overall survival data. The program operates without additional independent safety monitoring despite compressed timelines, representing what critics describe as a race to the bottom in regulatory standards.
Regulatory capture—when regulatory agencies advance the interests of regulated industries rather than the public—is difficult to prove definitively. It requires demonstrating not just financial dependency or revolving door employment, but systematic bias in decision-making that favors industry over public health.
The FDA's defenders argue that user fees solved a real problem: dangerous approval backlogs that delayed patient access to beneficial treatments. They point to breakthrough drugs for HIV, cancer, and rare diseases that reached patients faster under PDUFA than would have been possible with congressional funding alone. They note that the agency has withdrawn dangerous drugs and that most approvals involve genuinely effective treatments.
The critics point to structural incentives embedded in the funding model. When 65% of an agency's budget comes from the industry it regulates, and when performance metrics emphasize approval speed over safety monitoring, rational economic actors will prioritize activities that generate revenue. When senior officials routinely transition to pharmaceutical industry positions at multiples of government salaries, those officials rationally avoid confrontational relationships with potential future employers.
The evidence suggests something more subtle than outright corruption: a system that has evolved to serve industry priorities because the architecture of funding, employment pipelines, and performance metrics all align in that direction. Individual FDA officials may genuinely believe they are serving public health. The institutional structure they operate within rewards speed and approval over caution and surveillance.
What remains undisputed is the transformation of the FDA's financial foundation from public funding to industry dependence, the acceleration of approvals based on less rigorous evidence, the systematic underfunding of post-market safety monitoring, and the revolving door between regulatory authority and industry employment. Whether this constitutes capture depends on how one defines the term. That it creates conflicts of interest at the structural level is documented fact.
The FDA's dependency on pharmaceutical funding creates the regulatory framework within which specific drugs and vaccines enter the market. Part two examines how this framework shaped the COVID-19 vaccine development, approval, and monitoring process—including the $18 billion in public funding that flowed to pharmaceutical companies and the post-market safety surveillance systems that failed to track adverse events with the rigor pre-market approvals received. The same structural dynamics documented here—funding imbalances, accelerated pathways, industry negotiation of standards—played out in compressed timeframes with global consequences.